

Resource Summary Report

Generated by [nidm-terms](#) on Aug 10, 2026

Goat anti-Human IgG Fc Secondary Antibody, PE, eBioscience

RRID:AB_465926

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 12-4998-82, RRID:AB_465926)

Antibody Information

URL: http://antibodyregistry.org/AB_465926

Proper Citation: (Thermo Fisher Scientific Cat# 12-4998-82, RRID:AB_465926)

Target Antigen: Human IgG Fc

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: Flow
Consolidation on 1/2020: AB_465926, AB_10115324

Antibody Name: Goat anti-Human IgG Fc Secondary Antibody, PE, eBioscience

Description: This polyclonal secondary targets Human IgG Fc

Target Organism: human

Antibody ID: AB_465926

Vendor: Thermo Fisher Scientific

Catalog Number: 12-4998-82

Record Creation Time: 20251213T073341+0000

Record Last Update: 20260225T230501+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Human IgG Fc Secondary Antibody, PE, eBioscience.

No alerts have been found for Goat anti-Human IgG Fc Secondary Antibody, PE, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Chen D, et al. (2026) Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy. Cell reports. Medicine, 7(2), 102568.

Jones D, et al. (2026) Physiological febrile heat stress increases cytoadhesion through increased protein trafficking of Plasmodium falciparum surface proteins into the red blood cell. eLife, 14.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. Cancer research communications, 6(7), 1619.

Matar S, et al. (2025) Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile. Molecular cancer therapeutics, 24(6), 816.

Robles-Vera I, et al. (2025) Microbiota translocation following intestinal barrier disruption promotes Mincle-mediated training of myeloid progenitors in the bone marrow. Immunity, 58(2), 381.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer research communications, 5(3), 527.

Castaño D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell, 188(26), 7461.

Wu C, et al. (2025) Structural basis of human cytomegalovirus neutralization by gB AD-5-specific potent antibodies. Cell reports, 44(5), 115646.

Lal S, et al. (2025) Nanoparticle-formulated mRNA encoding engineered multivalent SIRP ?-Fc fusion proteins shows robust anti-cancer activity in preclinical models. Molecular therapy. Nucleic acids, 36(2), 102550.

Hammer Q, et al. (2024) Genetic ablation of adhesion ligands mitigates rejection of allogeneic cellular immunotherapies. Cell stem cell, 31(9), 1376.

Dou DR, et al. (2024) Xist ribonucleoproteins promote female sex-biased autoimmunity. *Cell*, 187(3), 733.

Grun CN, et al. (2024) Bacterial cell surface characterization by phage display coupled to high-throughput sequencing. *Nature communications*, 15(1), 7502.

Almazán NM, et al. (2023) Influenza-A mediated pre-existing immunity levels to SARS-CoV-2 could predict early COVID-19 outbreak dynamics. *iScience*, 26(12), 108441.

Harbour JC, et al. (2023) T helper 1 effector memory CD4+ T cells protect the skin from poxvirus infection. *Cell reports*, 42(5), 112407.

Frank F, et al. (2022) Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests. *Cell*, 185(19), 3603.

Shivange G, et al. (2021) A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. *Cell reports*, 37(5), 109953.

Tan AT, et al. (2021) Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. *Cell reports*, 34(6), 108728.

Okada R, et al. (2021) Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. *EBioMedicine*, 67, 103345.

Banach BB, et al. (2021) Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. *Cell reports*, 37(1), 109771.

Wiedermann U, et al. (2021) Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(13), 3649.